-
12:09:02 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

AURA Stock News

05/26/22 5:26 PM
Nasdaq : AURA
clinical triallow float
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in combination with immune checkpoint inhibitors. Cadmus Rich, Chief Medical officer and Head of...
RHEA-AI
neutral
05/12/22 4:15 PM
Nasdaq : AURA
earningsclinical triallow float
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2022, and provided clinical development and operational highlights. Orphan Drug Designation was recently granted to...
RHEA-AI
very positive
05/03/22 4:05 PM
Nasdaq : AURA
clinical triallow float
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU‑ 011. The results were presented as part of the 2022 Association of Research in Vision and...
RHEA-AI
neutral
03/23/22 4:15 PM
Nasdaq : AURA
earningsclinical triallow float
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided clinical development and operational highlights. We look forward to initiating the...
RHEA-AI
very positive
03/21/22 7:00 AM
Nasdaq : AURA
low float
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that the European Commission has granted Orphan Drug Designation to AU-011, its first VDC product candidate, for the treatment of uveal melanoma. “There are currently no...
RHEA-AI
very positive
03/15/22 7:00 AM
Nasdaq : AURA
conferenceslow float
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced it will host a virtual Investor Day on Tuesday, March 22, 2022, from 11:00 a.m. to 12:30 p.m. Eastern Time. Carol Shields, MD, Chief of the Ocular Oncology Service at Wills Eye...
RHEA-AI
neutral
03/08/22 4:30 PM
Nasdaq : AURA
conferencesclinical triallow float
Aura Biosciences to Present Preclinical Data Highlighting AU‑011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU-011 which is being developed for the treatment of life-threatening cancers with high unmet need,...
RHEA-AI
neutral
02/28/22 7:00 AM
Nasdaq : AURA
conferenceslow float
Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in the“ Auditory and Ophthalmology” panel discussion at the 42 nd Annual Cowen Virtual Health...
RHEA-AI
neutral